The Russian vaccine will be available for a period of 12 months
starting May 2021, it said in a statement. The Russian Direct
Investment Fund (RDIF), which is responsible for marketing the
vaccine abroad, said some deliveries could start in May but most
would be from June.
The 55-member AU hopes to see 60% of the continent's 1.3 billion
people immunised over roughly the next three years. But even as some
wealthier nations are well into their immunisation campaigns, just a
handful of countries in Africa have started to roll out vaccination
programmes.
"We are grateful to receive the Sputnik V vaccines from the Russian
Federation and tremendously proud to be able to offer them... for
our AU Member States," John Nkengasong, director of the AU's disease
control body, said in the statement.
"Bilateral and private sector partnerships such as these are
critical in our efforts to bring the COVID-19 pandemic to an end,"
Nkengasong added.
The AU previously said it had secured 270 million doses of
AstraZeneca, Pfizer and Johnson & Johnson vaccines for delivery this
year.
On Friday the vaccine team said all 270 million doses had been
"taken up by the first allocation phase deadline".
[to top of second column] |
Russia has marketed the Sputnik
V vaccine globally. It has struck manufacturing
deals with firms in India, South Korea and
Brazil, and has pledged to supply doses to
countries including Venezuela and Hungary.
The offer to the AU, if delivered in full, would be among its
biggest foreign supply deals to date.
While Moscow is touting such deals to highlight its role in fighting
the pandemic, exports of the vaccine have stirred concerns in
Russia, where authorities have struggled to roll out a nationwide
vaccination strategy.
In Africa, Algeria is already deploying the Sputnik V vaccine. And
after receiving an initial batch of a few dozen shots, Guinea is now
in talks to source around 400,000 doses, a health ministry official
said on Thursday.
South Africa's health ministry said this week that Sputnik V's
manufacturers had submitted documentation to the local medicines
regulator for registration.
(Additional reporting by Polina Ivanova in Moscow; Editing by Gareth
Jones)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |